Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARALAST Surveillance Study in Alpha1-Antitrypsin Deficiency
NCT00313144Phase 4Terminated
- Sponsor
- Takeda
- Start
- Jun 2006
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Started Jun 2006; status: terminated.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00313144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313144.